Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $52.4 million.

  • Zenas BioPharma's Total Current Liabilities rose 19.15% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 19.15%. This contributed to the annual value of $57.3 million for FY2024, which is 146.33% up from last year.
  • Latest data reveals that Zenas BioPharma reported Total Current Liabilities of $52.4 million as of Q3 2025, which was down 1.55% from $53.2 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Total Current Liabilities high stood at $57.3 million for Q4 2024, and its period low was $23.3 million during Q4 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $50.8 million (2025), whereas its average is $46.6 million.
  • Data for Zenas BioPharma's Total Current Liabilities shows a peak YoY soared of 146.33% (in 2024) over the last 5 years.
  • Zenas BioPharma's Total Current Liabilities (Quarterly) stood at $23.3 million in 2023, then spiked by 146.33% to $57.3 million in 2024, then rose by 19.15% to $52.4 million in 2025.
  • Its last three reported values are $52.4 million in Q3 2025, $53.2 million for Q2 2025, and $49.1 million during Q1 2025.